| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Glioblastoma | D005909 | 27 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Töyräs A et al. | Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. | 2003 | Eur J Pharm Sci | pmid:12885386 |
| Granshaw T et al. | Circadian rhythms in Neurospora crassa: farnesol or geraniol allow expression of rhythmicity in the otherwise arrhythmic strains frq10, wc-1, and wc-2. | 2003 | J. Biol. Rhythms | pmid:12932081 |
| Okazaki S et al. | [A 13-week subcutaneous toxicity study of prednisolone farnesylate (PNF) in rats]. | 1992 | J Toxicol Sci | pmid:1293320 |
| Nagashima Y et al. | [A 13-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 5 weeks]. | 1992 | J Toxicol Sci | pmid:1293321 |
| Nagashima Y et al. | [A 52-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 8 weeks]. | 1992 | J Toxicol Sci | pmid:1293322 |
| Taniguchi H et al. | [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF prior to and in the early stages of pregnancy in rats]. | 1992 | J Toxicol Sci | pmid:1293323 |
| Taniguchi H et al. | [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF during the period of fetal organogenesis in rats]. | 1992 | J Toxicol Sci | pmid:1293324 |
| Aso S et al. | [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--teratogenicity study in rabbits by subcutaneous administration]. | 1992 | J Toxicol Sci | pmid:1293325 |
| Taniguchi H et al. | [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study of subcutaneous administration of PNF during the perinatal and lactation periods in rats]. | 1992 | J Toxicol Sci | pmid:1293326 |
| Otsuka M et al. | [Mutagenicity studies of prednisolone farnesylate (PNF)]. | 1992 | J Toxicol Sci | pmid:1293327 |
| Uchiyama H et al. | [Effects of prednisolone farnesylate (PNF) gel on skin and ocular mucosa]. | 1992 | J Toxicol Sci | pmid:1293328 |
| Okazaki S et al. | [A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks]. | 1992 | J Toxicol Sci | pmid:1293330 |
| Okazaki S et al. | [A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks]. | 1992 | J Toxicol Sci | pmid:1293331 |
| Dietrich A et al. | Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. | 2003 | Biochem. J. | pmid:12952523 |
| Shchepin R et al. | Quorum sensing in Candida albicans: probing farnesol's mode of action with 40 natural and synthetic farnesol analogs. | 2003 | Chem. Biol. | pmid:12954333 |
| Giricz Z et al. | Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis. | 2003 | Basic Res. Cardiol. | pmid:12955403 |
| Cox AD et al. | Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. | 1992 | Mol. Cell. Biol. | pmid:1375323 |
| Lowe PN et al. | Expression of polyisoprenylated Ras proteins in the insect/baculovirus system. | 1992 | Biochem. Soc. Trans. | pmid:1397645 |
| Nigg EA et al. | Targeting lamin proteins to the nuclear envelope: the role of CaaX box modifications. | 1992 | Biochem. Soc. Trans. | pmid:1397650 |
| Akopyan TN et al. | Cleavage of farnesylated COOH-terminal heptapeptide of mouse N-ras by brain microsomal membranes: evidence for a carboxypeptidase which specifically removes the COOH-terminal methionine. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1417809 |